• Rabbit polyclonal antibodies (pAb) were used for preparing a gold-pAb conjugate, and the rGroEL-specific mouse monoclonal antibody was used as the antigen detection reagent at the ICT test line. (bvsalud.org)
  • The antibody is a mouse monoclonal antibody raised against VEGFA. (cloud-clone.com)
  • Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. (wikipedia.org)
  • [3] Antibody-drug conjugates are an example of bioconjugates and immunoconjugates . (wikipedia.org)
  • Home The Review Antibody-drug Conjugates What Are Customized ADCs? (adcreview.com)
  • As innovative next-generation immunotherapeutic agents, antibody-drug conjugates (ADCs) are being developed worldwide as a major strategy to combat cancer and other immunological disorders. (adcreview.com)
  • Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). (biomedcentral.com)
  • In addition to the above immunotherapeutic agents, conjugation of cytotoxic agents with monoclonal antibodies is an evolving field with the development of multiple targeted cytotoxic agents called antibody-drug conjugates (ADC) [ 45 ]. (biomedcentral.com)
  • Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. (springer.com)
  • Small-molecule inhibitors, antagonistic monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecific antibodies or biologics (bsAbs) and chimeric antigen receptor-modified T cells (CAR-Ts) targeting Notch signaling components have been developed as investigational anti-cancer drugs ( 10 - 12 ). (spandidos-publications.com)
  • Antibody-drug conjugates (ADCs) combine the advantages of high targeting of antibody drugs and high activity of Payload in tumor tissues, providing better efficacy than traditional antibody-based therapeutic agents and demonstrating great clinical value. (huatengsci.com)
  • Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
  • CD20, CD22, and CD30 are also targeted antigens of CAR T cells in ALL and lymphoma trials [ 26 ]. (biomedcentral.com)
  • Most important aspect of therapy is anti CD20 antibody, the Rituximab, which is a kind of immunotherapy or targeted therapy and attacks the CD20 antigen on the cancer cells. (lymphomaindia.com)
  • In recent years, tumor immunotherapy has achieved significant success in various cancers and has been one of the hotspots in the life sciences, especially immune checkpoint inhibitors and adoptive cellular therapy [ 3 ]. (hindawi.com)
  • Immune checkpoint inhibitors (ICIs) are antibodies that target crucial signaling pathways, such as programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), to improve the activation of T cells and enhance the immune response to cancer cells. (hindawi.com)
  • Small‑molecule γ‑secretase inhibitors (AL101, MRK‑560, nirogacestat and others) and antibody‑based biologics targeting Notch ligands or receptors [ABT‑165, AMG 119, rovalpituzumab tesirine (Rova‑T) and others] have been developed as investigational drugs. (spandidos-publications.com)
  • Immune checkpoint inhibitors such as the anti-programmed death 1 (PD-1) receptor antibodies have recently been approved to treat relapsed and refractory cHL and have significantly improved the outcome of patients with rrcHL. (wjon.org)
  • This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. (biomedcentral.com)
  • This has resulted in the development of additional immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and inhibitors of other immune checkpoints. (biomedcentral.com)
  • Entwicklung und Charakterisierung bispezifischer Antikörper-Derivate zur Immuntherapie CD19-positiver Leukämien und Lymphome [Development and characterisation of bispecific antibody derivatives for the immunotherapy of CD19-positive leukaemia and lymphoma] (Thesis) (in German and English). (wikipedia.org)
  • In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope's investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo's proprietary ADC technology for developing gatipotuzumab antibody drug conjugate. (wikipedia.org)
  • Customarily prepared antibody-drug conjugate (ADC) products refer to the conjugation of therapeutic antibodies against cancer surface antigens with different drug-linker complexes that serve the course of ADC development and evaluation. (adcreview.com)
  • One way to enhance therapeutic potential of antibodies is to conjugate them to small molecule drugs. (springer.com)
  • Lessons learned from the first-generation antibody-drug conjugate (ADC) and improvement of the technology guided the design of improved compounds which are now in clinical trials. (springer.com)
  • Teicher BA (2009) Antibody-drug conjugate targets. (springer.com)
  • Justia Patents Drug, Bio-affecting And Body Treating Compositions Patents Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material Patents Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g. (justia.com)
  • The discovery of novel mCD30 monoclonal antibodies (mAbs) using phage technology yielded 59 potential human single-chain variable fragments (HuscFvs). (bvsalud.org)
  • 495-497, 1975), MAbs were hailed as the 'Magic Bullet' that harnessed the therapeutic power of specific antibodies against specific diseases. (inscientioveritas.org)
  • ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug. (wikipedia.org)
  • The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
  • There is also a need for rational combinations beyond interleukin (IL)-2 and programmed death (PD)-1/ cytotoxic T-lymphocyte-associated antigen (CTLA)-4 immune checkpoint blockade and to combat exhaustion and restore costimulatory functions, e.g., with gene-engineered or pharmacologic agent-treated TILs. (biomedcentral.com)
  • Inotuzumab ozogamicin (INO), a CD22 antibody conjugated with calicheamicin is one of the newest ADCs. (biomedcentral.com)
  • Modification with chimeric antigen receptors (CARs) endows T cells with tumor specific cytotoxicity and thus induce anti-tumor immunity against malignancies. (ijbs.com)
  • Human derived T lymphocytes engineered to express chimeric antigen receptors, which are expanded in vitro culture and then infused into patients exerting robust cytotoxicity after tumor antigen recognition and subsequent activation. (biomedcentral.com)
  • It is comprised of an anti-CD22 monoclonal antibody (Inotuzumab) conjugated with the payload N-acetyl-gamma-calicheamicin via a bi-functional 4-(4-acetylphenoxy) butanoic acid linker. (adcreview.com)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
  • However, targeting solid tumors is more challenging than targeting B-cell malignancies with CAR-T cells because of the histopathological structure features, specific antigens shortage and strong immunosuppressive environment of solid tumors. (ijbs.com)
  • Nevertheless, targeting solid tumors is more challenging than targeting hematological malignancies because of tumor histopathological characteristics, shortage of specific antigens and local strong immunosuppressive microenvironment [ 4 ]. (ijbs.com)
  • Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. (lookformedical.com)
  • Immunotherapy is a promising approach for many oncological malignancies, including glioblastoma, however, there are currently no available tools or biomarkers to accurately assess whole-body immune responses in patients with glioblastoma treated with immunotherapy. (aacrjournals.org)
  • Therefore, the membrane epitope of CD30 (mCD30), left on the cancer cells, might be a prospective target for lymphoma treatment. (bvsalud.org)
  • The cytotoxicity assay of anti-mCD30-H4CART cells showed significant eradication of the CD30-expressing cell line, K562 (p = 0.0378). (bvsalud.org)
  • Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 10 6 cells in a suspension. (exbio.cz)
  • CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. (exbio.cz)
  • In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. (exbio.cz)
  • In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. (exbio.cz)
  • Separation of K562 cells stained using anti-human CD90 (Ber-H8) PE antibody (concentration in sample 5 μg/ml, red) from unstained K562 cells (black) in flow cytometry analysis (surface staining). (exbio.cz)
  • Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. (exbio.cz)
  • Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. (exbio.cz)
  • An anticancer drug is coupled to an antibody that targets a specific tumor antigen (or protein ) that, ideally, is only found in or on tumor cells. (wikipedia.org)
  • Antibodies attach themselves to the antigens on the surface of cancerous cells. (wikipedia.org)
  • Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)
  • However, from the beginning of puberty after thymus degeneration, human cytomegalovirus (HCMV) persists due to the chronic activation of cytomegalovirus in humans causing repeated activation of T cells, which is considered the driving factor of human immune aging [ 9 ]. (hindawi.com)
  • Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
  • T cells from a person with cancer are removed, genetically engineered to make a specific chimeric cell surface receptor with components from both a T-cell receptor and an antibody specific to a protein on the cancer cell, and transferred back to the person. (wikimili.com)
  • The gene encodes a chimaeric antigen receptor (CAR) that targets leukaemia cells. (wikimili.com)
  • Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. (biomedcentral.com)
  • Advances in our understanding on the interaction between the immune system and tumor cells have contributed to the rapid development of novel therapeutic strategies based on chimeric antigen receptor (CAR) or T cell receptor (TCR) modified T cells. (ijbs.com)
  • B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. (lookformedical.com)
  • LAVA Therapeutics is developing a Gammabody that engages V?9Vd2-T cells and a cascade of downstream immune cells to attack tumor cells expressing PSMA as a novel bispecific antibody therapeutic for the treatment of prostate cancer. (pegsummiteurope.com)
  • The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. (justia.com)
  • In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. (justia.com)
  • Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies. (justia.com)
  • In addition, many classical chemotherapeutic anti-cancer agents kill cancer cells by directly damaging their DNA, which produces high toxicity due to its non-specificity [ 3 ] . (oaepublish.com)
  • Here, the utility of OX40, a costimulatory molecule mainly expressed on activated effector T cells known to play an important role in eliminating cancer cells, was evaluated as a PET imaging biomarker to quantify and track response to immunotherapy. (aacrjournals.org)
  • One is the ability to administer large numbers of highly selected cells with high avidity for tumor antigens that can recognize shared and patient-specific mutated (neo) antigens. (biomedcentral.com)
  • Committed stem cells can mature to become antigen-processing cells, with some possessing phagocytic capabilities. (medscape.com)
  • The importance of dendritic cells in presenting antigens to T and B lymphocytes is increasingly recognized. (medscape.com)
  • [ 11 ] Immature dendritic cells respond to GM-CSF (not to macrophage colony-stimulating factor [M-CSF]) and become committed to generating dendritic cells, which are "professional" antigen-presenting cells (APCs). (medscape.com)
  • [ 12 ] These cells can capture antigen and migrate to lymphoid organs, where they present the antigens to naive T cells. (medscape.com)
  • Effective induction of antigen-specific T-cell responses requires interaction between the dendritic cells and T lymphocytes to prime the latter cells for expansion and subsequent immune responses. (medscape.com)
  • However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relapse), which highly correlate with poor CAR T cells persistence. (biomedcentral.com)
  • Adcetris is formulated by the conjugation of brentuximab, an anti-CD30 (also known as TNFRSF8) monoclonal antibody with payload monomethyl auristatin E (MMAE) via a cleavable peptide linker. (adcreview.com)
  • Brentuximab vedotin (Adcetris ® ), an anti-CD30 antibody conjugated to a potent microtubule inhibitor for the treatment of Hodgkin's lymphoma and anaplastic large cell lymphomas, is the only marketed ADC today. (springer.com)
  • Adoptive cellular therapy, especially chimeric antigen receptor (CAR) T cell therapy, has gained unprecedented success among hematologic tumors [ 11 ]. (hindawi.com)
  • CAR-T cell therapy has achieved outstanding progresses in clinical observations, which makes it even more attractive in the development of cancer adoptive immunotherapy. (ijbs.com)
  • This combination is expected to bring together the benefits of highly potent drugs on the one hand and selective binders of specific tumor antigens on the other hand. (springer.com)
  • Ly6C high MC presented downregulated co-stimulatory receptors (CD2, GITR, and TIM1) which direct immune cell proliferation, and upregulated co-stimulatory ligands (LIGHT and SEMA4A) which trigger antigen priming and differentiation. (frontiersin.org)
  • Unlike antibodies that target extracellular proteins, T cell receptors can target intracellular proteins, processed into peptides, and brought to the surface by HLA. (pegsummiteurope.com)
  • In addition, polyclonal antibodies from hyperimmunized sheep, horses and rabbits are used as antidotes against envenomization (snake and spider venom), certain bacterial toxins (such as Clostridium botulinum neurotoxin), digitalis toxicity, as well as to cause immune suppression in organ transplant recipients to prevent rejection ( 3 ). (inscientioveritas.org)
  • Tumor immunotherapy brings substantial and long-term clinical benefits that can even cure tumors. (hindawi.com)
  • Tumor immunotherapy refers to novel therapeutic measures that turn the immune system into a destructive force against tumors [ 1 ]. (hindawi.com)
  • Optimization of the design of CAR vectors, exploration of new targets, addition of safe switches and combination with other treatments bring new vitality to the CAR-T cell based immunotherapy against solid tumors. (ijbs.com)
  • A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. (lookformedical.com)
  • However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. (biomedcentral.com)
  • The ligand for CD30 is CD30L (CD153). (exbio.cz)
  • The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. (justia.com)
  • In this study, an immunochromatographic antigen detection test kit (ICT AgTK) that targets the highly conserved O. tsutsugamushi 60 kDa GroEL chaperonin (heat shock protein 60) was developed. (bvsalud.org)
  • Briefly, the antibody portion of Kadcyla, trastuzumab (trade name Herceptin) is a humanized IgG1 monoclonal antibody that specifically targets HER2 while its payload, DM1, is also a mitosis inhibitor and functions by disrupting tubulin polymerization. (adcreview.com)
  • Thus, it is imperative to develop more competent and safer immunotherapy approaches by optimizing the design of CAR vectors, exploring new targets, incorporating conditional safe switches and combining with other strategies. (ijbs.com)
  • Brentuximab is a chimeric IgG1 monoclonal antibody that is developed by grafting the mouse anti-CD30 antibody CDR onto a human Fc framework while the payload, MMAE, an antimitotic agent, is an auristatin derivative that inhibits mitosis by impeding tubulin polymerization. (adcreview.com)
  • We generated chimeric antigen receptor-modified T lymphocytes using HuscFv #A4 as an antigen detection part (anti-mCD30-H4CART). (bvsalud.org)
  • thus, PIM2 kinase is a rational target of anti-cancer therapeutics. (bvsalud.org)
  • At the same time, there was an increasing appreciation of the fact that, although antimicrobials work (and work well) by slowing down and/or killing the microbial pathogens, the totality of host defence is a dynamic process dependent upon host-pathogen interactions - because of which immune therapies, including antibody-associated therapies, had a definite and important role to play in clinical therapeutics. (inscientioveritas.org)
  • Given the unique characteristic of high antigen-specificity of Monoclonal Antibodies or MAb(s) (which I touched upon briefly in the previous post ), it is expected that the practice of antibody therapeutics would embrace this technology. (inscientioveritas.org)
  • However, the CD30 antigen releases the soluble ectodomain of CD30, which might obscure the targeted therapy. (bvsalud.org)
  • Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. (exbio.cz)
  • By addressing key synthesis bottlenecks in discovery cycles, researchers can now rapidly evaluate candidate immunotherapy biologics at speeds previously unattainable. (pegsummiteurope.com)
  • Pembrolizumab (Keytruda), a humanized monoclonal anti-PD-1 antibody, is the first anti-PD-1 antibody approved by the FDA for the treatment of patients with unresectable or metastatic melanoma, non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, and gastric/gastroesophageal junction cancer [ 4 - 10 ]. (hindawi.com)
  • The distribution of grade 3-4 neurologic ir-AEs frequency was 0.7% among patients receiving anti-CTLA-4 (ipilimumab and tremelimumab), 0.4% among patients receiving anti-PD1 (nivolumab, pembrolizumab, lambrolizumab, and pidilizumab), and 0.7% among patients receiving a combination therapy (anti-CTLA-4 + anti-PD1) [ 20 ]. (hindawi.com)
  • Integration of human intelligence, cognitive computing and explainable artificial intelligence is necessary to construct a Notch‑related knowledge‑base and optimize Notch‑targeted therapy for patients with cancer. (spandidos-publications.com)
  • Multiagent chemotherapy + immunotherapy should be reserved for patients who are having advanced stages of disease and having symptoms/ difficulties related to it. (lymphomaindia.com)
  • These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. (biomedcentral.com)
  • 1 , 7 Consensus guidelines in this difficult-to-treat population are challenging to create given the small numbers of patients and multiple treatment options in this era of burgeoning cellular and immunotherapy. (jnccn.org)
  • The payload-linker is conjugated to the antibody via Cys residues. (adcreview.com)
  • Creative Biolabs's one-stop ADC development service is full-ranged, extending from the starting point: antibody identification and screening, linker and drug selection, antibody-linker-drug conjugation all the way to the final destination: ADC in vitro & in vivo analysis. (adcreview.com)
  • However, designing an ADC is more complex than a simple meccano game, requiring thoughtful combination of antibody, linker, and drugs in the context of a target and a defined cancer indication. (springer.com)
  • Other compounds, such as CMC-544, SAR3419, CDX-011, PSMA-ADC, BT-062, and IMGN901 currently in clinical trials, targeting varied antigens and bearing different linker and drugs, contribute to the learning curve of ADC, as do the discontinued ADC. (springer.com)
  • ScFv is the antigen-binding domain of CAR structure, which is composed of a single heavy and light chain of monoclonal antibody connected by a linker. (biomedcentral.com)
  • Although this challenge was somewhat resolved by the 1930s through better-purified antibodies, the introduction of vastly superior, potent, and better tolerated antimicrobial chemotherapy ('antibiotics', starting with sulphonamides and then the β-lactam, penicillin) around 1935 sounded the death-knell for serum therapy. (inscientioveritas.org)
  • Polypeptides, such as antibody molecules and TCR molecules, and methods of making the same, are disclosed. (justia.com)
  • The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. (justia.com)
  • CD30 acts as a costimulatory molecule in thymic negative selection. (exbio.cz)
  • They are fragments antigen-binding (Fab or Fab') of two different monoclonal antibodies and are linked by chemical means like a thioether. (wikipedia.org)
  • Here, we produced human single-chain antibody fragments (HuscFvs) to PIM2 by using phage display library, which was constructed in a way that a portion of phages in the library carried HuscFvs against human own proteins on their surface with the respective antibody genes in the phage genome. (bvsalud.org)
  • TCRs can recognize fragments of antigen attached to MHC on the surface of an APC. (medscape.com)
  • Numerous clinical trials and real-world experience provide evidence of improved response and survival outcomes with multiple immunotherapy agents and different combinations in various cancers. (biomedcentral.com)
  • In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. (justia.com)
  • Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. (springer.com)
  • CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. (exbio.cz)
  • We systematically examined and proved that our HuscFv #A4 could specifically eradicate CD30-expressing cancers. (bvsalud.org)
  • Clinical activity of TIL therapy has also been reported in other cancer types, including human papillomavirus-associated cancers, cholangiocarcinoma, non-small-cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). (biomedcentral.com)
  • Biological therapies play an increasing role in cancer treatment, although the number of naked antibodies showing clinical efficacy as single agent remains limited. (springer.com)
  • The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions. (justia.com)
  • Germline mutations in the NOTCH1 , NOTCH2 and NOTCH3 genes cause Adams-Oliver syndrome, Alagille syndrome and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, respectively ( 4 ), and DLL4-NOTCH3 signaling in human vascular organoids induces basement membrane thickening and drives vasculopathy in the diabetic microenvironment ( 5 ). (spandidos-publications.com)
  • The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. (exbio.cz)
  • Not surprisingly, this situation resulted in a renewed interest in immune-based therapies, including antibody therapy, aimed at combating disease by buttressing host immunity. (inscientioveritas.org)
  • Novel platforms for creating off-the-shelf therapies including cell therapy and antibody-based approaches will be discussed. (pegsummiteurope.com)